$12.18
0.00%
Nasdaq, Aug 30, 01:59 am CET
ISIN
US71722W1071
Symbol
PHAT

Phathom Pharmaceuticals Inc Stock price

$12.18
+3.56 41.30% 1M
+6.66 120.65% 6M
+4.06 50.00% YTD
-4.12 25.28% 1Y
+3.68 43.29% 3Y
-24.58 66.87% 5Y
-12.42 50.49% 10Y
-12.42 50.49% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.18 1.46%
ISIN
US71722W1071
Symbol
PHAT
Industry

Key metrics

Basic
Market capitalization
$864.1m
Enterprise Value
$1.3b
Net debt
$424.1m
Cash
$149.6m
Shares outstanding
70.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.6 | 5.1
EV/Sales
11.3 | 7.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-67.0%
Return on Equity
131.8%
ROCE
-169.8%
ROIC
-
Debt/Equity
-1.4
Financials (TTM | estimate)
Revenue
$114.0m | $169.9m
EBITDA
$-268.3m | $-168.9m
EBIT
$-269.0m | $-194.7m
Net Income
$-330.2m | $-243.8m
Free Cash Flow
$-274.9m
Growth (TTM | estimate)
Revenue
1,049.6% | 207.5%
EBITDA
-6.4% | 39.0%
EBIT
-6.4% | 29.8%
Net Income
-11.1% | 27.1%
Free Cash Flow
-26.7%
Margin (TTM | estimate)
Gross
86.9%
EBITDA
-235.2% | -99.4%
EBIT
-235.9%
Net
-289.5% | -143.5%
Free Cash Flow
-241.0%
More
EPS
$-4.6
FCF per Share
$-3.9
Short interest
28.2%
Employees
427
Rev per Employee
$130.0k
Show more

Is Phathom Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Phathom Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

Buy
87%
Hold
13%

Financial data from Phathom Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
114 114
1,050% 1,050%
100%
- Direct Costs 15 15
658% 658%
13%
99 99
1,147% 1,147%
87%
- Selling and Administrative Expenses 333 333
52% 52%
292%
- Research and Development Expense 36 36
16% 16%
31%
-268 -268
6% 6%
-235%
- Depreciation and Amortization 0.73 0.73
1% 1%
1%
EBIT (Operating Income) EBIT -269 -269
6% 6%
-236%
Net Profit -330 -330
11% 11%
-290%

In millions USD.

Don't miss a Thing! We will send you all news about Phathom Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Phathom Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
7 days ago
FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:
Neutral
GlobeNewsWire
12 days ago
FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom.
Neutral
Seeking Alpha
25 days ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Eric Sciorilli - Corporate Participant Robert Breedlove - VP of Finance & Principal Accounting Officer Steven L. Basta - CEO, President & Director Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Robert S...
More Phathom Pharmaceuticals Inc News

Company Profile

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Head office United States
CEO Steven Basta
Employees 427
Founded 2018
Website www.phathompharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today